References
-
1
Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR.
Remission in schizophrenia: proposed criteria and rationale for consensus.
Am J Psychiatr.
2005;
162
441-449
-
2
Apud JA, Egan MF, Wyatt RJ.
Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis.
Schizophr Res.
2003;
63
151-160
-
3
Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G. et al .
Defining treatment refractoriness in schizophrenia.
Schizophr Bull.
1990;
16
551-561
-
4
Chouinard G.
Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment.
Schizophr Res.
1991;
5
21-33
-
5
Chouinard G, Jones BD.
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.
Am J Psychiatr.
1980;
137
16-21
-
6
Fernandez HH, Trieschmann ME, Okun MS.
Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease.
Mov Dis.
2005;
20
104-105
-
7
Gaebel W, Janner M, Frommann N, Pietzcker A, Kopcke W, Linden M. et al .
First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies.
Schizophr Res.
2002;
53
145-159
-
8
Gaebel W, Weinmann S, Sartorius N, Rutz W, MacIntyre JS.
Schizophrenia practice guidelines: international survey and comparison.
Br J Psychiatr.
2005;
187
248-255
-
9
Goldman HH, Gatozzi AA, Taube CA.
Defining and counting the chronically mentally ill.
Hosp Comm Psychiatr.
1981;
32
21-27
-
10
Ho BC, Andreasen NC, Flaum M, Nopoulos P, Miller D.
Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia.
Am J Psychiatr.
2000;
157
808-815
-
11
Kane JM, Leucht S, Carpenter D, Docherty JP.
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
J Clin Psychiatr.
2003;
64
((Suppl 12))
5-19
-
12
Kirkpatrick B, Alphs L, Buchanan RW.
The concept of supersensitivity psychosis.
J Nerv Ment Dis.
1992;
180
265-270
-
13
Lerner V, Bergman J, Borokhov A, Loewenthal U, Miodownik C.
Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy.
Clin Neuropharmacol.
2005;
28
66-71
-
14
Leucht S, Lasser R.
The concepts of remission and recovery in schizophrenia.
Pharmacopsychiatry.
2006;
39
161-170
-
15
Lu ML, Pan JJ, Teng HW, Su KP, Shen WW.
Metoclopramide-induced supersensitivity psychosis.
Ann Pharmacother.
2002;
36
1387-1390
-
16
Margolese HC, Chouinard G, Beauclair L, Belanger MC.
Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder.
J Clin Psychopharmacol.
2002;
22
347-352
-
17
Meador KG, Taylor JA, Thapa PB, Fought RL, Ray WA.
Predictors of antipsychotic withdrawal or dose reduction in a randomized controlled trial of provider education.
J Am Geriatr Soc.
1997;
45
207-210
-
18
Meltzer HY, Lee MA, Ranjan R, Mason EA, Cola PA.
Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine.
Psychopharmacology (Berl).
1996;
124
176-187
-
19
Moncrieff J.
Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse.
Acta Psychiatr Scand.
2006;
114
3-13
-
20
Moncrieff J.
Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem.
Med Hypotheses.
2006;
67
517-523
-
21
Suzuki T, Uchida H, Tanaka KF, Tomita M, Tsunoda K, Nomura K. et al .
Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia.
Int Clin Psychopharmacol.
2003;
18
323-329
-
22
Tollefson GD, Dellva MA, Mattler CA, Kane JM, Wirshing DA, Kinon BJ.
Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.
J Clin Psychopharmacol.
1999;
19
435-443
-
23
Verghese C, Leon J De, Nair C, Simpson GM.
Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics.
Biol Psychiatr.
1996;
39
135-138
-
24
Viguera AC, Baldessarini RJ, Hegarty JD, Kammen DP van, Tohen M.
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.
Arch Gen Psychiatr.
1997;
54
49-55
Correspondence
Dr. J. D. Molina
Acute Inpatient Unit Coordinator
Doctor R. Lafora Psychiatric Hospital
Carretera de Colmenar Viejo
Km. 13,800
28049 Madrid
Spain
Telefon: +34/91/586 76 33
eMail: candrader@medynet.com
